Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XTIKTR
- Development stage
- Unknown
- Lead developer
- Regrow Biosciences
- Modality
- Cell Therapies
- Administration
- Intraurethral
01
Overview
XTIKTR is an autologous epithelial cell therapy developed by Regrow Biosciences for the treatment of urethral stricture. The therapy involves harvesting a patient's own epithelial cells, which are then processed and implanted at the site of the stricture. Once implanted, these cells facilitate the regeneration of a new epithelialization layer, effectively restoring the natural urethral tissue and relieving symptoms. Developed in partnership with the Department of Biotechnology (DBT) of the Government of India, XTIKTR was launched in 2020 as a biological alternative to traditional surgical interventions for urological conditions.
- Brand names
- XTIKTR
- Other names
- XTIKTR™
Beyond the preview
Go deeper on XTIKTR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XTIKTR.